Clinical Trials on KRAS, NRAS, HRAS-mutated NSCLC

Total 227 results

Lupin Ltd.

Completed

A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

United Kingdom, Netherlands, Belgium
Elicio Therapeutics

Recruiting

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P)

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12R | KRAS G12V | KRAS G12C | KRAS G12A | KRAS G12S | KRAS G13D | NRAS G12V | NRAS G12C | NRAS G12S

United States
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Non-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

United States
Nested Therapeutics, Inc

Recruiting

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628)

Glioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene Mutation

United States, Australia
University Health Network, Toronto
Bayer; AstraZeneca; Amgen; AnHeart Therapeutics Inc.; Applied Health Research Centre and other collaborators

Recruiting

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) (CARMA-BROS)

Cancer | Malignancies Multiple | Malignant Solid Tumor | Cancer, Therapy-Related | Molecular Sequence Variation | Genetic Alteration | Gene Fusion | Receptor Tyrosine Kinase Gene Mutation | RTK Family Gene Mutation | Ras (Kras or Nras) Gene Mutation

Canada
University Health Network, Toronto

Completed

A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer

Colorectal Cancer | KRAS Wildtype | NRAS Wildtype | BRAF Wildtype

Canada
Calithera Biosciences, Inc

Completed

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

NSCLC | Solid Tumors | KRAS Gene Mutation | CRC

United States
Cardiff Oncology
Pfizer

Recruiting

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Metastatic Colorectal Cancer | CRC | KRAS/NRAS Mutation

United States
University of Utah

Terminated

Regorafenib + Panitumumab for Colorectal Cancers

KRAS and NRAS Wild-type Colorectal Cancer

United States
Chinese PLA General Hospital
Zhejiang University

Recruiting

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Solid Tumor, Adult | KRAS G12D | EphA2 Overexpression | KRAS G12V | KRAS G12C

China
N.N. Petrov National Medical Research Center of...

Recruiting

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations (NТО-RAS)

Melanoma | Lung Cancer | Pancreas Cancer | Refractory Cancer | Colorectal Cancer Recurrent | RAS Mutation | Ras (Kras or Nras) Gene Mutation

Russian Federation
Henan Cancer Hospital

Completed

Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer

Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
Intergroupe Francophone de Cancerologie Thoracique
Amgen

Active, not recruiting

RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC (LungKG12Ci)

Nsclc | KRAS P.G12C

France
D3 Bio (Wuxi) Co., Ltd

Recruiting

A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

KRAS P.G12C

Australia, Korea, Republic of, China, United States, Hong Kong
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

KRAS G12C

China
Amgen

Active, not recruiting

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

Finland, United States, Canada, Belgium, Spain, Korea, Republic of, Netherlands, United Kingdom, Australia, Denmark, Hungary, Sweden, Taiwan, Greece, Russian Federation, Switzerland, France, Italy, Japan, Poland, Brazil, Germany, Po...
Hunan Province Tumor Hospital

Recruiting

Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer (KILLER)

Non-small Cell Lung Cancer | KRAS G12D | KRAS G12R | KRAS G12V | KRAS G12C | KRAS G12Y | KRAS G13N

China
Addario Lung Cancer Medical Institute

Recruiting

Studying Pathways of Resistance in KRAS-driven Cancers (SPARK)

KRAS P.G12C

United States
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Solid Tumors, KRAS Mutation

Spain, United Kingdom, United States, Belgium
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

Solid Tumors, KRAS Mutation

Japan
Karen-Lise Garm Spindler

Completed

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - (OPTIPAL-II)

Colorectal Cancer Metastatic | KRAS Gene Mutation | Circulating Tumor DNA | BRAF Gene Mutation | NRAS Gene Mutation | Epidermal Growth Factor Receptor Inhibitor

Denmark
Dr.Laurent Mineur
Merck Serono International SA; BESPIM, CHU Nîmes (data analysis)

Unknown

PREMIUM, Observational Study

First Line WT KRAS mCRC

France
King Saud Medical City

Active, not recruiting

"Analgesic Efficacy of Combined Transversus Abdominis Plane Block and Posterior Rectus Sheath Block in Patients Undergoing Laparoscopic Appendectomy"

ERAS

Saudi Arabia
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Solid Tumors, KRAS Mutation; SOS1

United States, Netherlands, Germany
Providence Health & Services

Available

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

KRAS G12V Mutant Advanced Epithelial Cancers
Cairo University

Recruiting

Enhanced Recovery After Surgery (ERAS)Guidelines in Mitral Valve Surgeries, Questionnaire

ERAS

Egypt
Shanghai Zhongshan Hospital

Recruiting

The Impact of ERAS Program in Cardiac Surgery on Patient Prognosis

ERAS

China
Tanta University

Completed

Effect of Regional Anesthesia on Enhanced Recovery After Spine Surgeries

ERAS

Egypt
University of Milano Bicocca

Completed

ERAS in Liver Surgery (ERASliver)

ERAS

Italy
OnKure, Inc.

Active, not recruiting

NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Melanoma | NRAS Gene Mutation | RAS Mutation

United States
Suzhou Genhouse Bio Co., Ltd.
Zhejiang Cancer Hospital

Not yet recruiting

GH21 Combined With D-1553 With Advanced Solid Tumors

KRAS G12C Mutant Solid Tumors
University of Thessaly

Recruiting

A Greek-designed ERAS Protocol in Elective Craniotomy (ERAS)

Craniotomy | ERAS

Greece
Georgetown University
Immune System Key Ltd

Recruiting

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Solid Tumor | KRAS Mutation-Related Tumors

United States
Minia University

Not yet recruiting

Comparison of Outcome Between (ERACS) Versus Traditional Methods in Elective CS (ERACS)

ERAS
Ataturk University

Not yet recruiting

Web-Based Education on ERAS Protocols Applied in Gynecological and Obstetric Surgery

ERAS
University of Pennsylvania

Completed

Enhanced Recovery After Spine Surgery Randomized Clinical Trial (ERASS)

ERAS

United States
Dr. Soetomo General Hospital

Completed

Preliminary Survey in Preparation for the Implementation of ERAS at Dr Soetomo Hospital

ERAS

Indonesia
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Solid Tumor, KRAS Mutation

United States, Taiwan, Japan
xCures
Cancer Commons

Available

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States
Cliniques universitaires Saint-Luc- Université...

Completed

Enhanced Recovery in Esophageal Surgery

ERAS Protocol, Esophagectomy

Belgium
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

KRAS G12C Mutant Advanced Solid Tumors

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Solid Tumor | KRAS Mutation-Related Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
Amgen

Active, not recruiting

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

KRAS p.G12C Mutant Advanced Solid Tumors

United States, France, Canada, Spain, Belgium, Korea, Republic of, Austria, Australia, Hungary, Greece, Germany, Japan, Romania, Switzerland, Brazil, Portugal
BeBetter Med Inc
Xiangya Hospital of Central South University

Recruiting

Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

Advanced or Metastatic Solid Tumor | KRAS G12C Mutation

China
Boehringer Ingelheim

Completed

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Solid Tumors, KRAS Mutation

Japan
Zeynep Kamil Maternity and Pediatric Research and...

Enrolling by invitation

Outcomes of Enhanced Recovery After Cesarean (ERAC) Protocol

Cesarean Section Complications | ERAS

Turkey
Vanderbilt University Medical Center
Edwards Lifesciences

Completed

Enhanced Recovery After Surgery in Colorectal Surgery: A Large-Scale Quality Improvement Project (ERAS)

Colorectal Surgery | Perioperative Care | Quality Improvement | ERAS

United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Spain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India

Clinical Trials on KRAS, NRAS, HRAS-mutated NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations